Esophageal Adenocarcinoma After Antireflux Surgery in a Cohort Study From the 5 Nordic Countries

Research output: Contribution to journalJournal articlepeer-review

Standard

Esophageal Adenocarcinoma After Antireflux Surgery in a Cohort Study From the 5 Nordic Countries. / Maret-Ouda, John; Santoni, Giola; Wahlin, Karl; Artama, Miia; Brusselaers, Nele; Farkkila, Martti; Lynge, Elsebeth; Mattsson, Fredrik; Pukkala, Eero; Romundstad, Pal; Tryggvadottir, Laufey; Von Euler-Chelpin, My; Lagergren, Jesper.

In: Annals of Surgery, Vol. 274, No. 6, 2021, p. E535-E540.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Maret-Ouda, J, Santoni, G, Wahlin, K, Artama, M, Brusselaers, N, Farkkila, M, Lynge, E, Mattsson, F, Pukkala, E, Romundstad, P, Tryggvadottir, L, Von Euler-Chelpin, M & Lagergren, J 2021, 'Esophageal Adenocarcinoma After Antireflux Surgery in a Cohort Study From the 5 Nordic Countries', Annals of Surgery, vol. 274, no. 6, pp. E535-E540. https://doi.org/10.1097/SLA.0000000000003709

APA

Maret-Ouda, J., Santoni, G., Wahlin, K., Artama, M., Brusselaers, N., Farkkila, M., Lynge, E., Mattsson, F., Pukkala, E., Romundstad, P., Tryggvadottir, L., Von Euler-Chelpin, M., & Lagergren, J. (2021). Esophageal Adenocarcinoma After Antireflux Surgery in a Cohort Study From the 5 Nordic Countries. Annals of Surgery, 274(6), E535-E540. https://doi.org/10.1097/SLA.0000000000003709

Vancouver

Maret-Ouda J, Santoni G, Wahlin K, Artama M, Brusselaers N, Farkkila M et al. Esophageal Adenocarcinoma After Antireflux Surgery in a Cohort Study From the 5 Nordic Countries. Annals of Surgery. 2021;274(6):E535-E540. https://doi.org/10.1097/SLA.0000000000003709

Author

Maret-Ouda, John ; Santoni, Giola ; Wahlin, Karl ; Artama, Miia ; Brusselaers, Nele ; Farkkila, Martti ; Lynge, Elsebeth ; Mattsson, Fredrik ; Pukkala, Eero ; Romundstad, Pal ; Tryggvadottir, Laufey ; Von Euler-Chelpin, My ; Lagergren, Jesper. / Esophageal Adenocarcinoma After Antireflux Surgery in a Cohort Study From the 5 Nordic Countries. In: Annals of Surgery. 2021 ; Vol. 274, No. 6. pp. E535-E540.

Bibtex

@article{20dd50b6a4564b4fa192fdd23da85c01,
title = "Esophageal Adenocarcinoma After Antireflux Surgery in a Cohort Study From the 5 Nordic Countries",
abstract = "Objective: We aimed to clarify the long-term risk development of EAC after antireflux surgery.Summary of Background Data: Gastroesophageal reflux disease (GERD) increases EAC risk, but whether antireflux surgery prevents EAC is uncertain.Methods: Multinational, population-based cohort study including individuals with GERD from all 5 Nordic countries in 1964–2014. First, EAC risk after antireflux surgery in the cohort was compared with the corresponding background population by calculating standardized incidence ratios (SIRs) with 95% confidence intervals (95% CIs). Second, multivariable Cox proportional hazards regression, providing hazard ratios (HRs) with 95% CIs, compared EAC risk in GERD patients with antireflux surgery with those with nonsurgical treatment.Results: Among 942,071 GERD patients, 48,863 underwent surgery and 893,208 did not. Compared to the corresponding background population, EAC risk did not decrease after antireflux surgery [SIR 4.90 (95% CI 3.62–6.47) 1–<5 years and SIR 4.57 (95% CI 3.44–5.95) ≥15 years after surgery]. Similarly, no decrease was found for patients with severe GERD (esophagitis or Barrett esophagus) after surgery [SIR 6.09 (95% CI 4.39–8.23) 1–<5 years and SIR = 5.27 (95% CI 3.73–7.23) ≥15 years]. The HRs of EAC were stable comparing the surgery group with the nonsurgery group with GERD [HR 1.71 (95% CI 1.26–2.33) 1–<5 years and HR 1.69 (95% CI 1.24–2.30) ≥15 years after treatment], or for severe GERD [HR 1.56 (95% CI 1.11–2.20) 1–<5 years and HR 1.57 (95% CI 1.08–2.26) ≥15 years after treatment].Conclusions: Surgical treatment of GERD does not seem to reduce EAC risk.",
keywords = "esophageal neoplasm, fundoplication, population-based, proton pump inhibitor, risk",
author = "John Maret-Ouda and Giola Santoni and Karl Wahlin and Miia Artama and Nele Brusselaers and Martti Farkkila and Elsebeth Lynge and Fredrik Mattsson and Eero Pukkala and Pal Romundstad and Laufey Tryggvadottir and {Von Euler-Chelpin}, My and Jesper Lagergren",
year = "2021",
doi = "10.1097/SLA.0000000000003709",
language = "English",
volume = "274",
pages = "E535--E540",
journal = "Advances in Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams & Wilkins",
number = "6",

}

RIS

TY - JOUR

T1 - Esophageal Adenocarcinoma After Antireflux Surgery in a Cohort Study From the 5 Nordic Countries

AU - Maret-Ouda, John

AU - Santoni, Giola

AU - Wahlin, Karl

AU - Artama, Miia

AU - Brusselaers, Nele

AU - Farkkila, Martti

AU - Lynge, Elsebeth

AU - Mattsson, Fredrik

AU - Pukkala, Eero

AU - Romundstad, Pal

AU - Tryggvadottir, Laufey

AU - Von Euler-Chelpin, My

AU - Lagergren, Jesper

PY - 2021

Y1 - 2021

N2 - Objective: We aimed to clarify the long-term risk development of EAC after antireflux surgery.Summary of Background Data: Gastroesophageal reflux disease (GERD) increases EAC risk, but whether antireflux surgery prevents EAC is uncertain.Methods: Multinational, population-based cohort study including individuals with GERD from all 5 Nordic countries in 1964–2014. First, EAC risk after antireflux surgery in the cohort was compared with the corresponding background population by calculating standardized incidence ratios (SIRs) with 95% confidence intervals (95% CIs). Second, multivariable Cox proportional hazards regression, providing hazard ratios (HRs) with 95% CIs, compared EAC risk in GERD patients with antireflux surgery with those with nonsurgical treatment.Results: Among 942,071 GERD patients, 48,863 underwent surgery and 893,208 did not. Compared to the corresponding background population, EAC risk did not decrease after antireflux surgery [SIR 4.90 (95% CI 3.62–6.47) 1–<5 years and SIR 4.57 (95% CI 3.44–5.95) ≥15 years after surgery]. Similarly, no decrease was found for patients with severe GERD (esophagitis or Barrett esophagus) after surgery [SIR 6.09 (95% CI 4.39–8.23) 1–<5 years and SIR = 5.27 (95% CI 3.73–7.23) ≥15 years]. The HRs of EAC were stable comparing the surgery group with the nonsurgery group with GERD [HR 1.71 (95% CI 1.26–2.33) 1–<5 years and HR 1.69 (95% CI 1.24–2.30) ≥15 years after treatment], or for severe GERD [HR 1.56 (95% CI 1.11–2.20) 1–<5 years and HR 1.57 (95% CI 1.08–2.26) ≥15 years after treatment].Conclusions: Surgical treatment of GERD does not seem to reduce EAC risk.

AB - Objective: We aimed to clarify the long-term risk development of EAC after antireflux surgery.Summary of Background Data: Gastroesophageal reflux disease (GERD) increases EAC risk, but whether antireflux surgery prevents EAC is uncertain.Methods: Multinational, population-based cohort study including individuals with GERD from all 5 Nordic countries in 1964–2014. First, EAC risk after antireflux surgery in the cohort was compared with the corresponding background population by calculating standardized incidence ratios (SIRs) with 95% confidence intervals (95% CIs). Second, multivariable Cox proportional hazards regression, providing hazard ratios (HRs) with 95% CIs, compared EAC risk in GERD patients with antireflux surgery with those with nonsurgical treatment.Results: Among 942,071 GERD patients, 48,863 underwent surgery and 893,208 did not. Compared to the corresponding background population, EAC risk did not decrease after antireflux surgery [SIR 4.90 (95% CI 3.62–6.47) 1–<5 years and SIR 4.57 (95% CI 3.44–5.95) ≥15 years after surgery]. Similarly, no decrease was found for patients with severe GERD (esophagitis or Barrett esophagus) after surgery [SIR 6.09 (95% CI 4.39–8.23) 1–<5 years and SIR = 5.27 (95% CI 3.73–7.23) ≥15 years]. The HRs of EAC were stable comparing the surgery group with the nonsurgery group with GERD [HR 1.71 (95% CI 1.26–2.33) 1–<5 years and HR 1.69 (95% CI 1.24–2.30) ≥15 years after treatment], or for severe GERD [HR 1.56 (95% CI 1.11–2.20) 1–<5 years and HR 1.57 (95% CI 1.08–2.26) ≥15 years after treatment].Conclusions: Surgical treatment of GERD does not seem to reduce EAC risk.

KW - esophageal neoplasm

KW - fundoplication

KW - population-based

KW - proton pump inhibitor

KW - risk

U2 - 10.1097/SLA.0000000000003709

DO - 10.1097/SLA.0000000000003709

M3 - Journal article

C2 - 31800492

VL - 274

SP - E535-E540

JO - Advances in Surgery

JF - Advances in Surgery

SN - 0003-4932

IS - 6

ER -

ID: 286005177